Viropin Pharmaceutical
Viropin aims to stop pandemics by anticipating and neutralizing infectious diseases before they threaten people. It pursues this with a three-pronged approach: surveillance via proprietary AI, diagnostics through VariantVault, and treatments for drug-resistant microbes. Core technologies include AI, a cutting-edge microbe library called VariantVault, and proprietary sterilants, decolonizers, and antiviral products. The company targets public health and research organizations, partnering with others to advance disease control. Viropin seeks to scale globally to mitigate antimicrobial resistance and future outbreaks.
Viropin Pharmaceutical
Viropin aims to stop pandemics by anticipating and neutralizing infectious diseases before they threaten people. It pursues this with a three-pronged approach: surveillance via proprietary AI, diagnostics through VariantVault, and treatments for drug-resistant microbes. Core technologies include AI, a cutting-edge microbe library called VariantVault, and proprietary sterilants, decolonizers, and antiviral products. The company targets public health and research organizations, partnering with others to advance disease control. Viropin seeks to scale globally to mitigate antimicrobial resistance and future outbreaks.